These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 28256574)

  • 1. Tissue-specific tumorigenesis: context matters.
    Schneider G; Schmidt-Supprian M; Rad R; Saur D
    Nat Rev Cancer; 2017 Apr; 17(4):239-253. PubMed ID: 28256574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering the universe of genetic context-dependencies using mouse models of cancer.
    Falcomatà C; Bärthel S; Schneider G; Saur D; Veltkamp C
    Curr Opin Genet Dev; 2019 Feb; 54():97-104. PubMed ID: 31078084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune modulatory effects of oncogenic KRAS in cancer.
    Hamarsheh S; Groß O; Brummer T; Zeiser R
    Nat Commun; 2020 Oct; 11(1):5439. PubMed ID: 33116132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells.
    Kumazaki M; Shimomura I; Kiyono T; Ochiya T; Yamamoto Y
    Biochem Biophys Res Commun; 2020 Apr; 525(2):483-490. PubMed ID: 32111352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic context shapes the fitness landscape of tumor suppression.
    Blair LM; Juan JM; Sebastian L; Tran VB; Nie W; Wall GD; Gerceker M; Lai IK; Apilado EA; Grenot G; Amar D; Foggetti G; Do Carmo M; Ugur Z; Deng D; Chenchik A; Paz Zafra M; Dow LE; Politi K; MacQuitty JJ; Petrov DA; Winslow MM; Rosen MJ; Winters IP
    Nat Commun; 2023 Oct; 14(1):6422. PubMed ID: 37828026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold.
    Posada IM; Serulla M; Zhou Y; Oetken-Lindholm C; Abankwa D; Lectez B
    PLoS One; 2016; 11(7):e0159677. PubMed ID: 27437940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.
    Bteich F; Mohammadi M; Li T; Bhat MA; Sofianidi A; Wei N; Kuang C
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current state of the art and future trends in RAS-targeted cancer therapies.
    Punekar SR; Velcheti V; Neel BG; Wong KK
    Nat Rev Clin Oncol; 2022 Oct; 19(10):637-655. PubMed ID: 36028717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage response.
    Grabocka E; Commisso C; Bar-Sagi D
    Clin Cancer Res; 2015 Mar; 21(6):1243-7. PubMed ID: 25424849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.
    Parikh N; Shuck RL; Nguyen TA; Herron A; Donehower LA
    Mol Cancer Res; 2012 Jun; 10(6):845-55. PubMed ID: 22532587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.
    Collins MA; Bednar F; Zhang Y; Brisset JC; Galbán S; Galbán CJ; Rakshit S; Flannagan KS; Adsay NV; Pasca di Magliano M
    J Clin Invest; 2012 Feb; 122(2):639-53. PubMed ID: 22232209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions.
    Watterson A; Coelho MA
    Cell Commun Signal; 2023 Mar; 21(1):45. PubMed ID: 36864508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo.
    Najumudeen AK; Fey SK; Millett LM; Ford CA; Gilroy K; Gunduz N; Ridgway RA; Anderson E; Strathdee D; Clark W; Nixon C; Morton JP; Campbell AD; Sansom OJ
    Nat Commun; 2024 Jan; 15(1):100. PubMed ID: 38168062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.
    Grabocka E; Pylayeva-Gupta Y; Jones MJ; Lubkov V; Yemanaberhan E; Taylor L; Jeng HH; Bar-Sagi D
    Cancer Cell; 2014 Feb; 25(2):243-56. PubMed ID: 24525237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagy and Tumorigenesis.
    Liu W; Meng Y; Zong C; Zhang S; Wei L
    Adv Exp Med Biol; 2020; 1207():275-299. PubMed ID: 32671755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
    Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
    Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model for RAS mutation patterns in cancers: finding the sweet spot.
    Li S; Balmain A; Counter CM
    Nat Rev Cancer; 2018 Dec; 18(12):767-777. PubMed ID: 30420765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crosstalk of Ras and Rho: activation of RhoA abates Kras-induced liver tumorigenesis in transgenic zebrafish models.
    Chew TW; Liu XJ; Liu L; Spitsbergen JM; Gong Z; Low BC
    Oncogene; 2014 May; 33(21):2717-27. PubMed ID: 23812423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Senescent Macrophages Promote KRAS-Driven Lung Tumorigenesis.
    Cancer Discov; 2023 Aug; 13(8):1758. PubMed ID: 37326376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.